Executive Summary / Key Takeaways
-
The Physicians Realty merger transformed Healthpeak into the dominant outpatient medical platform, delivering $70 million in synergies and sector-leading 3.8% same-store NOI growth in 2025, while creating the scale to internalize property management across 39 million square feet—directly improving tenant retention to 85% and re-leasing spreads to 5%.
-
Lab segment earnings have reached a cyclical trough in 2026, with management guiding to a 5-10% same-store NOI decline as occupancy losses from the biotech funding winter finally flow through income statements—yet new supply is going to zero, capital markets are improving, and the company is acquiring distressed assets like the Gateway portfolio at what will likely prove to be CLI cyclical lows.
-
The Janus Living IPO represents a unique value unlock mechanism, allowing Healthpeak to monetize its senior housing portfolio at a higher multiple while retaining majority ownership and external management fees—effectively creating a captive pure-play vehicle to capture demographic tailwinds without diluting core focus.
-
Capital allocation discipline is the defining competitive advantage, evidenced by selling $1.4 billion of stabilized outpatient assets at 6.3% cap rates, buying back stock at implied 8-10% yields, and recycling proceeds into lab acquisitions with "way into the double digits" return potential—creating immediate accretion while peers remain passive.
-
2026 guidance ($1.70-$1.74 FFO) reflects a clear earnings bottom, with outpatient medical (2-3% growth) and senior housing (8-12% growth) partially mitigating the lab drag, setting up a potential inflection as lab occupancy improves by year-end 2026 and the $1 billion capital recycling plan funds higher-return investments.
Setting the Scene: A Healthcare REIT Built for Cyclical Arbitrage
Healthpeak Properties, founded in 1985, operates as an umbrella partnership REIT (UPREIT) with a portfolio deliberately concentrated across three healthcare real estate sectors: outpatient medical buildings, life science labs, and senior housing communities. This triad matters because each segment operates on different cyclical clocks—outpatient medical benefits from secular demographic shifts and policy tailwinds, life science labs are tied to biotech funding cycles, and senior housing follows supply/demand dynamics in specific markets. By maintaining material exposure to all three, Healthpeak can rotate capital from late-cycle sectors into early-cycle ones, a strategy that has defined its recent transformation.
The company makes money through triple-net leases (79% of outpatient buildings are on hospital campuses), specialized lab facilities with premium rents ($90 per square foot versus $38 for outpatient), and RIDEA-structured senior housing where the company participates in operational upside. What distinguishes Healthpeak from pure-play competitors is this deliberate sectoral diversification combined with geographic concentration in high-barrier markets—59% of lab square footage in San Francisco, 22% in Boston, and 17% in San Diego. These markets feature the densest concentration of biotech talent and capital, creating network effects where tenants cluster near peers, research institutions, and venture funding sources.
Healthpeak sits in an industry structure where scale and relationships determine leasing success. The merger with Physicians Realty Trust in March 2024 created the largest outpatient medical platform in the sector, with 299 buildings and the critical mass to internalize property management—a move that improved tenant satisfaction scores and drove retention to 85%. This operational control creates a data feedback loop that competitors using third-party managers cannot replicate, allowing Healthpeak to identify tenant needs faster and deploy technology solutions more rapidly.
Technology, Products, and Strategic Differentiation
Healthpeak's competitive moat rests on three pillars: specialized infrastructure, internalized property management, and counter-cyclical capital deployment. The specialized infrastructure matters because lab buildings require advanced electrical, mechanical, and HVAC systems that cost materially more to construct than standard office space—creating a supply constraint that benefits incumbents when demand returns. The company's 210 acres in South San Francisco, representing one-third of the submarket's land, is not just a real estate position but a strategic barrier to entry that prevents competitors from replicating its cluster effect.
Internalizing property management across 39 million square feet is a strategic decision that directly impacts the bottom line. By eliminating third-party managers, Healthpeak captures the management fee margin while gaining direct tenant relationships and operational data. This enabled the company to achieve $70 million in synergies from the Physicians Realty merger—synergies that helped mitigate lab segment weakness and allowed Healthpeak to grow its dividend through the downturn. The direct relationships also facilitate technology deployment, including an enterprise-wide AI operating system and "agentic" capabilities that optimize leasing and asset management decisions.
The counter-cyclical capital allocation strategy is perhaps the most differentiated aspect of Healthpeak's approach. While peers like Welltower (WELL) and Ventas (VTR) focus on steady-state growth, Healthpeak actively times cycles. Management halted capital deployment to Life Science in 2021, avoiding the peak development frenzy. Then, as the biotech funding winter created distress in 2024-2025, Healthpeak acquired the Gateway portfolio in South San Francisco—1.4 million square feet with 500,000 square feet of vacancy—at a price that appears opportunistic. This demonstrates discipline: selling stabilized outpatient assets at 6.3% cap rates while buying distressed lab assets with "high single digit unlevered returns" and "way into the double digits" potential creates accretion that passive strategies cannot match.
Financial Performance & Segment Dynamics: Reading the Sectoral Tea Leaves
The 2025 financial results show three sectors at different inflection points. Total revenue reached $2.82 billion, but the segment composition reveals the strategic rotation underway. Outpatient medical generated $1.27 billion in revenue with 3.8% same-store NOI growth and 92% occupancy—performance that exceeded the high end of guidance and demonstrated the power of the integrated platform. Lab revenue declined modestly to $860 million with same-store NOI growth of 1.5% and occupancy falling from 96% to 95%, reflecting the biotech funding winter's impact. Senior housing surged to $604 million with 12.6% same-store NOI growth and occupancy rising to 87%, driven by the unique entry-fee model that broadens demand.
The outpatient medical segment is generating stable, bond-like cash flows with 5% re-leasing spreads and 85% tenant retention—defensive earnings that often command premium valuations in a slowing economy. Meanwhile, the lab segment is absorbing the cyclical pain that management anticipated, with the $176 million impairment on South San Francisco JVs representing a non-cash mark-to-market that clears the deck for recovery. The senior housing segment's 17% same-store growth in Q4 2025 validates the decision to contribute these assets to Janus Living, as pure-play senior housing REITs trade at higher multiples than diversified healthcare REITs.
The balance sheet metrics support this rotation strategy. Net debt to adjusted EBITDA of 5.2x and $2.4 billion of liquidity provide the firepower to execute the $1 billion capital recycling plan without issuing equity at a discounted stock price. The debt-to-equity ratio of 1.22 is higher than Welltower's 0.49 but lower than Ventas' 1.02, reflecting Healthpeak's willingness to use leverage opportunistically while maintaining investment-grade ratings (Baa1/BBB). This gives the company optionality: it can fund acquisitions through asset sales, debt, or retained cash flows depending on market conditions.
Cash flow generation validates the strategy. Annual operating cash flow of $1.28 billion and free cash flow of $1.15 billion represent a 9.27x price-to-FCF multiple—substantially lower than Welltower's 48.17x or Ventas' 38.95x. This valuation disconnect exists despite Healthpeak's 7.11% dividend yield being the highest among its peer group, with a conservative 72% AFFO payout ratio that provides dividend security. Healthpeak is generating more cash per dollar of market value than competitors, yet trades at a discount due to lab segment uncertainty—creating potential upside if the lab recovery materializes.
Outlook, Management Guidance, and Execution Risk
Management's 2026 guidance of $1.70-$1.74 FFO per share represents a 5-8% decline from 2025's $1.84, framing this as the earnings trough. The guidance assumes outpatient medical grows 2-3%, senior housing grows 8-12%, and lab declines 5-10%—a scenario where the defensive segments stabilize the portfolio but do not fully overcome the lab drag. This sets a clear baseline: any upside to lab occupancy or leasing velocity will flow directly to earnings, while further deterioration is already incorporated.
The key assumption underlying the guidance is that lab occupancy will improve by year-end 2026. Management bases this on three factors: new supply going to zero for several years, over 4 million square feet of lab inventory being removed from the supply pipeline as landlords pivot to alternative uses, and a leasing pipeline that is roughly twice the size of the pipeline at the start of the year. The lag between signing leases and recognizing income explains why 2026 remains pressured—large 60,000 square foot leases require 12-18 months of buildout and rent commencement. This creates a timing mismatch that obscures the underlying recovery, potentially causing the market to undervalue the stock at the exact moment fundamentals are turning.
Execution risk centers on the $1 billion capital recycling plan. Management has $200 million under contract, meaning $800 million depends on achieving target pricing in a potentially softening real estate market. If asset sales cannot be completed at target cap rates, the company may need to fund acquisitions with debt, increasing leverage above the target mid-5x range. Conversely, successful execution at cap rates better than the implied stock price would be immediately accretive. The Janus Living IPO, which raised $840 million in March 2026, partially de-risks this by providing capital without diluting Healthpeak shareholders.
The refinancing calendar presents another execution hurdle. Approximately $1.1 billion of debt matures in 2026, with $650 million of senior unsecured notes in July and $440 million of mortgages throughout the year. Refinancing costs are higher today than in-place levels, which will create an FFO headwind. However, the company's ability to issue $500 million of 4.75% notes at a 92 basis point spread in August 2025—one of the tightest investment-grade REIT 7-year spreads year-to-date—demonstrates continued access to attractively priced capital. The market recognizes Healthpeak's credit quality despite segment headwinds, providing confidence that refinancing can be managed.
Risks and Asymmetries: What Could Break the Thesis
The primary risk is that the lab recovery takes longer than management anticipates. While capital markets improved in late 2025, with M&A activity at three times 2024 levels and an IPO backlog building, this could prove temporary if interest rates rise or regulatory uncertainty returns. Each 100 basis points of lab occupancy decline impacts earnings by $0.01-$0.015 per share, meaning a further 500 basis point drop would reduce FFO by $0.05-$0.075—material but not catastrophic. The bigger concern is that tenants continue to delay leasing decisions, pushing recovery into 2027 and extending the earnings trough.
Interest rate risk cuts both ways. While the Fed cut rates three times in 2025, any reversal would pressure biotech funding and increase Healthpeak's refinancing costs. The company has reduced floating rate debt to almost zero, which mitigates near-term exposure but means future debt will be issued at prevailing higher rates. This caps the upside from rate cuts while preserving downside if rates rise—a structurally defensive position that prioritizes stability over opportunistic leverage.
The senior housing segment, while performing well with 12.6% same-store growth, faces execution risk from the Janus Living transition. As an external manager, Healthpeak's alignment depends on its retained ownership stake and management fees. If Janus Living's public market performance disappoints, Healthpeak's contributed assets could be marked down, and the external management model may face governance scrutiny. However, the 50%+ NOI growth potential in the SWF SH JV assets, which Healthpeak now owns 100% after the $312 million buyout, provides a powerful offset that could drive senior housing performance even if Janus Living struggles.
A final asymmetry lies in the outpatient medical segment's durability. Management expects the outpatient portfolio to outperform other sectors if the economy slows and sees minimal impact from tariffs due to limited import exposure. This defensive characteristic means Healthpeak's largest segment acts as a stabilizer during downturns, potentially allowing the company to take more lab risk than pure-play life science REITs. If recession fears intensify, this quality could drive a relative valuation re-rating versus more cyclical peers.
Competitive Context and Positioning
Healthpeak's competitive position is best understood through segment-by-segment comparisons. In outpatient medical, the Physicians Realty merger created a premier platform and portfolio, with 96% of buildings affiliated with hospital systems versus Ventas' more fragmented mix. Hospital-affiliated buildings command higher rents and better retention than non-affiliated properties, creating a structural advantage that Welltower's seniors-heavy portfolio cannot replicate. Healthpeak's 92% occupancy and 5% re-leasing spreads compare favorably to the broader medical office market, suggesting pricing power that comes from scale and location quality.
In life science labs, Healthpeak competes directly with Ventas and Alexandria Real Estate (ARE), but with a counter-cyclical twist. While peers continued developing labs through 2022-2023, Healthpeak halted capital deployment in 2021, avoiding the oversupply that now plagues the market. Healthpeak's 95% occupancy, while down from 98% in 2023, is still above market averages and its balance sheet is not burdened with empty development projects. The Gateway acquisition positions Healthpeak to capture upside as the market recovers, while competitors are still digesting their development pipelines.
The senior housing comparison reveals Healthpeak's strategic innovation. While Welltower and Ventas operate large SHOP portfolios directly, Healthpeak's entry-fee CCRC model generates $200 million of annual NOI, 50% higher than 2019 levels, with a net entry fee at 60% of local median home value. This affordability-driven approach broadens the demand pool and differentiates the product, allowing 87% occupancy versus the sector's typical 80-85%. The Janus Living IPO further differentiates Healthpeak by creating a pure-play vehicle that can trade at a premium multiple.
Financially, Healthpeak trades at 9.27x price-to-FCF, a significant discount to Welltower and Ventas. This valuation gap exists despite Healthpeak's 7.11% dividend yield being the highest in the peer group and its payout ratio of 72% being the most conservative. The market is pricing Healthpeak as a distressed lab REIT while ignoring the stability of its outpatient platform and the optionality of its senior housing unlock. If lab occupancy inflects as management predicts, this valuation gap should close rapidly, providing asymmetric upside.
Valuation Context
At $16.70 per share, Healthpeak trades at 9.27x TTM free cash flow and 4.11x sales, representing a substantial discount to healthcare REIT peers. The enterprise value of $21.28 billion implies an EV/EBITDA multiple of 13.68x, below Ventas (23.27x) and Welltower (57.62x) when adjusted for growth prospects. This suggests the market is not paying a premium for Healthpeak's counter-cyclical strategy, creating potential value for investors who believe management can execute the lab recovery.
The dividend yield of 7.11% is the highest among direct peers, including Omega Healthcare Investors (OHI) at 5.98% and Sabra Health Care REIT (SBRA) at 6.10%, while the AFFO payout ratio of 72% provides ample coverage. This combination of high yield and low payout ratio is unusual and signals that either the market doubts the sustainability of earnings or the stock is undervalued. Given that 2026 guidance shows an earnings trough with recovery potential, the latter interpretation appears more plausible.
Debt-to-equity of 1.22x is higher than Welltower's 0.49x but lower than Ventas' 1.02x when considering total leverage. Net debt to adjusted EBITDA of 5.2x is within management's target range and supported by $2.4 billion of liquidity. Healthpeak is using moderate leverage to amplify returns on counter-cyclical investments without reaching the leverage levels that would threaten dividend security during downturns.
The price-to-book ratio of 1.55x compares favorably to Welltower (3.25x) and Ventas (3.12x), suggesting the market is not assigning a premium to Healthpeak's assets. This is particularly notable given the company's 210 acres in South San Francisco and its hospital-affiliated outpatient portfolio, which should command premium valuations. The discount likely reflects uncertainty around lab recovery timing, creating a valuation opportunity if management's inflection thesis proves correct.
Conclusion
Healthpeak Properties has engineered a strategic transformation that positions it to capture value across three distinct healthcare real estate cycles. The Physicians Realty merger created a defensive outpatient platform generating stable cash flows with sector-leading retention and re-leasing spreads. The lab segment is absorbing the final earnings impact of a biotech funding winter that management correctly anticipated by halting development in 2021, setting up a recovery as new supply goes to zero and capital markets improve. The Janus Living IPO unlocks value from the senior housing portfolio while maintaining upside participation through external management fees and majority ownership.
The central thesis hinges on two variables: the timing of lab occupancy recovery and the execution of the $1 billion capital recycling plan. Management's guidance for 2026 explicitly frames this as an earnings trough, with lab declines partially offset by outpatient and senior housing strength. If lab leasing accelerates as the pipeline suggests, 2027 earnings could inflect positively, compressing the 9.27x free cash flow multiple and narrowing the valuation gap with peers.
For investors, Healthpeak offers a rare combination: a 7.11% dividend yield with 72% AFFO coverage, a counter-cyclical capital allocation strategy that has historically timed markets well, and exposure to a lab recovery that is not yet priced into the stock. The risks are material—lab recovery could be delayed, asset sales might not achieve target pricing, and refinancing costs will pressure 2026 FFO—but these are well-telegraphed and reflected in guidance. Healthpeak is not a passive healthcare REIT but an active capital allocator positioned to create value through sector rotation, making the current earnings trough an opportune entry point for investors who believe management's cycle-timing expertise will deliver recovery-driven outperformance.
